Merck and Moderna Phase 3 Trial Cuts Melanoma Recurrence by 42%

The Three-Question Framework

What Happened?

Merck and Moderna announced results from the global Phase 3 INTerpath-001 trial showing that intismeran autogene (V940/mRNA-4157) combined with pembrolizumab (Keytruda) reduced the risk of recurrence or death by 42% (HR=0.58, p<0.001) in 1,137 patients with resected stage IIB–IV melanoma.

Why It Matters

This establishes the first Phase 3 validation that individualized neoantigen mRNA vaccines targeting patient-specific tumor mutations produce durable clinical efficacy in the adjuvant setting over standard checkpoint immunotherapy.

What Could Happen Next

Merck and Moderna are engaging global regulatory authorities for marketing authorization while advancing nine Phase 2 and 3 INTerpath trials across non-small cell lung cancer, gastric carcinoma, and pancreatic ductal adenocarcinoma.

Executive Key Takeaways

Intismeran plus Keytruda achieved a two-year recurrence-free survival rate of 82.2% versus 70.0% for Keytruda alone across 1,137 randomized patients.

Distant metastasis or death was reduced by 38% (HR=0.62, p=0.002) with 2-year DMFS reaching 88.5% compared to 80.2% for the active comparator arm.

Following the six-month immunization window, sensitivity analysis demonstrated a 58% reduction in recurrence or death (piecewise HR=0.42).

Source: Merck and Moderna's joint presentation at the ESMO 2026 Presidential Symposium (Presentation #LBA1) and formal clinical release on October 22, 2026, alongside acceptance in The New England Journal of Medicine.

The double-blind, active-controlled INTerpath-001 trial (ClinicalTrials.gov identifier NCT05933577) enrolled 1,137 participants who underwent complete surgical resection of high-risk cutaneous melanoma. Patients were randomized 2:1 to receive either intismeran (1 mg intramuscularly every three weeks for up to nine doses) alongside pembrolizumab (400 mg intravenously every six weeks for approximately one year), or placebo paired with pembrolizumab for a 56-week maximum course.

Intismeran autogene is manufactured using proprietary next-generation sequencing and bioinformatic algorithms that analyze both tumor tissue and germline DNA. The resulting synthetic single-stranded messenger RNA encodes up to 34 patient-specific neoantigens, prompting host antigen-presenting cells to express and display mutated peptide epitopes to circulating cytotoxic T lymphocytes.

In the pre-specified modified intent-to-treat cohort, excluding participants who failed to receive at least one dose of the assigned intervention, the combination reduced the hazard of recurrence or death by 49% (HR=0.51, 95% CI 0.39–0.67). While efficacy during the initial six-month priming window mirrored pembrolizumab monotherapy (HR=0.99), divergence widened sharply once neoantigen-specific immune memory matured, cutting long-term metastatic risk in half.

Treatment-related adverse events occurred in 95.8% of combination patients compared to 90.0% receiving pembrolizumab monotherapy, with Grade 3 to 5 toxicities remaining balanced at 14.2% versus 13.4%. The most prevalent adverse reactions attributed to intismeran were transient pyrexia (52.2%), injection-site soreness (51.0%), and generalized fatigue (38.5%).

What remains to be established is overall survival maturity, as median follow-up stands at 24.6 months with survival events still accumulating. Additionally, commercial turnaround times for bespoke mRNA manufacturing and logistical pricing frameworks for individualized immunotherapy will determine global health system uptake.

The Three-Question Framework

What Happened?

Why It Matters

What Could Happen Next

Executive Key Takeaways

Primary Sources & Citations